Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
The goal of this clinical research study is to learn the most tolerable dose of Nexavarâ (sorafenib) when given in combination with Mobozilâ (plerixafor) and Neupogenâ (filgrastim) to patients with AML. The safety of this combination will also be studied. Funding Source - FDA OOPD
Critère d'inclusion
- Acute myelogenous leukemia,leukemia